Vanguard Capital Management
BEAM icon

Vanguard Capital Management’s Beam Therapeutics BEAM Stock Holding History

Vanguard Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$158M Buy
4,599,437
+222,063
+5% +$6.7M ﹤0.01% 1294
2026
Q1 		$104M Buy
+4,377,374
New +$121M ﹤0.01% 1447

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management's BEAM Position: Q2 2026 in Review

Vanguard Capital Management increased its Beam Therapeutics (BEAM) stake by 5.1% in Q2 2026, buying an estimated $6.7M and bringing the position to 4,599,437 shares worth $158M. The position accounts for ﹤0.01% of the portfolio, ranked #1294.

Vanguard Capital Management first reported a position in BEAM in Q1 2026 and has held it in 2 quarters since. 274 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Vanguard Capital Management held 4,599,437 shares of Beam Therapeutics worth $158M as of Q2 2026.
  • Vanguard Capital Management bought 222,063 Beam Therapeutics shares in Q2 2026, an estimated $6.7M.
  • Beam Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1294 holding.
  • Vanguard Capital Management first reported a position in Beam Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 274 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.